Evelo Biosciences Inc (OTCPK:EVLO)

$ 0.06 0 (0%) Market Cap: 1.14 Mil Enterprise Value: 17.82 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Evelo Biosciences Inc Extraordinary Shareholders Meeting Transcript
Jan 26, 2024
Evelo Biosciences Inc Clinical Updates Call Transcript
Apr 26, 2023
Q4 2022 Evelo Biosciences Inc Earnings Call Transcript
Mar 16, 2023

$5.98 (-5.08%)

Earnings
Evelo Biosciences Inc To Provide Business Update Transcript
Feb 01, 2023
Evelo Biosciences Inc Scientific Basis for SINTAX Medicines in Frontiers in Immunology - Corporate Call Transcript
Nov 30, 2022
Evelo Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 Evelo Biosciences Inc Earnings Call Transcript
Aug 11, 2022

$57.8 (-2.03%)

Earnings
Q4 2021 Evelo Biosciences Inc Earnings Call Transcript
Mar 24, 2022

$82.4 (+25.99%)

Earnings
Evelo Biosciences Inc KOL Event - Corporate Call Transcript
Mar 11, 2022
Q3 2021 Evelo Biosciences Inc Earnings Call Transcript
Oct 28, 2021

$165.4 (+2.99%)

Earnings
Evelo Biosciences Inc EDP1815 Clinical Data Update Call Transcript
Sep 27, 2021
Q2 2021 Evelo Biosciences Inc Earnings Call Transcript
Jul 29, 2021

$202.2 (+8.83%)

Earnings
Q1 2021 Evelo Biosciences Inc Earnings Call Transcript
Apr 29, 2021

$244.8 (+1.24%)

Earnings
Q4 2020 Evelo Biosciences Inc Earnings Call Transcript
Mar 09, 2021

$219 (+11.05%)

Earnings
Evelo Biosciences, Inc. - Special Call Transcript
Jan 20, 2021
Evelo Biosciences, Inc. - Special Call Transcript
Dec 09, 2020
Q3 2020 Evelo Biosciences Inc Earnings Call Transcript
Oct 29, 2020

$86.8 (-4.82%)

Earnings
Evelo Biosciences, Inc. - Special Call Transcript
Oct 22, 2020
Evelo Biosciences Inc at Morgan Stanley 18th Annual Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Q2 2020 Evelo Biosciences Inc Earnings Call Transcript
Jul 30, 2020

$79.6 (+2.84%)

Earnings
Evelo Biosciences Inc Annual Shareholders Meeting Transcript
Jun 17, 2020
Q1 2020 Evelo Biosciences Inc Earnings Call Transcript
May 11, 2020

$109.6 (+7.87%)

Earnings
Evelo Biosciences, Inc. - Special Call Transcript
May 07, 2020
Q4 2019 Evelo Biosciences Inc Earnings Call Transcript
Feb 13, 2020

$87.8 (-10.95%)

Earnings
Q3 2019 Evelo Biosciences Inc Earnings Call Transcript
Nov 05, 2019

$135 (-3.71%)

Earnings
Evelo Biosciences Inc to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815 Call Transcript
Oct 04, 2019
Evelo Biosciences Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Q2 2019 Evelo Biosciences Inc Earnings Call Transcript
Aug 06, 2019

$118 (+5.92%)

Earnings
Q1 2019 Evelo Biosciences Inc Earnings Call Transcript
May 02, 2019

$169.6 (-0.24%)

Earnings
Q4 2018 Evelo Biosciences Inc Earnings Call Transcript
Feb 14, 2019

$191.8 (+9.73%)

Earnings

Q3 2019 Evelo Biosciences Inc Earnings Call Transcript

Nov 05, 2019 / 01:30PM GMT

Release Date Price: $135 (-3.71%)

Transcript 10-Q8-K

Operator

Good morning, and welcome to Evelo's conference call to discuss the interim clinical data from its Phase Ib trial of EDP1815. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed.

Jessica Cotrone

Evelo Biosciences, Inc. - VP & Head of Communications

Thank you, operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.evelobio.com under the Investors tab.

Today on our call, Simba Gill, Chief Executive Officer; Duncan McHale, Chief Medical Officer; and Mark Bodmer, President of R&D and Chief Scientific Officer, will review the positive interim clinical data for EDP1815 and discuss its significance for our strategy and future development plans.

Before we begin, I would like to remind everyone that statements made during this conference call that do not

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.